Brief: Zealand Pharma Announces Positive Phase 2 Zupreme-2 Topline Results For Amylin Analog Petrelintide In People With Overweight Or Obesity And Type 2 Diabetes
07/10/2026 18:17
BRIEF-Zealand Pharma Announces Positive Phase 2 Zupreme-2 Topline Results For Amylin Analog Petrelintide In People With Overweight Or Obesity And Type 2 Diabetes Oct 7 (Reuters) - Zealand Pharma A/S ZELA.CO:
REG-ZEALAND PHARMA ANNOUNCES POSITIVE PHASE 2 ZUPREME-2 TOPLINE RESULTS FOR AMYLIN ANALOG PETRELINTIDE IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES
ZEALAND PHARMA - CO AND ROCHE INITIATE PHASE 3A PROGRAM FOR PETRELINTIDE
Source text: ID:nGNEbDncXs
Further company coverage: ZELA.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey